🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Another example of our 2 tier healthcare system when it comes to cancer. If you have private health insurance, you can access cutting-edge treatments that are denied to public cancer patients. UCAN IRELAND

The next chapter in #BTK inhibitors now in print. Randomized ph3 with FDA registration intent. Study of #pirtobrutinib (non-covalent BTK) vs investigators choice in setting of post covalent BTK inhibitor. 3rd Generation BTK inhibitor ascopubs.org/doi/10.1200/JC…

The European Commission has approved a fixed-duration Bruton’s tyrosine kinase (BTK) selective inhibitor, Calquence (acalabrutinib) plus venetoclax, with or without obinutuzumab, to treat adults with previously untreated chronic lymphocytic leukaemia pharmaceutical-technology.com/news/ec-astraz…

Delighted to talk about our All-Island Cancer Research Institute (AICRI) AICRIstart project and our amazing set of emerging cancer researchers receiving top level training at key partners institutions across the island of Ireland Mark Lawler UCD Research Research Ireland University College Dublin The Patrick G Johnston Centre for Cancer Research

On the topic of anti-cancer drug reimbursement in Ireland: Until relatively recently, the role of a medical oncologist was to weigh up the probable benefits and toxicities of the best available anticancer therapy, and offer professional advice, based on data and experience on

Briallant symposium on CLL European Hematology Association chaired by Ruth Clifford . Fidelma Hackett Carmel Ann Galligan Haematology Association of Ireland Nurses & AHPs HSE Mid West

Proud to see and hear the strong Irish participation at #EHA25. Ruth Clifford at the panel discussion on leveraging efficacy in this new fixed duration era of #CLL Also great to see our clinical nurse specialists Fidelma Hackett Ger Walpole and Mary Kelly Jan Rynne

CLL Advocates Network at #EHA25 poster and abstract focus on advancing shared decision-making in CLL, ensuring that care reflects the individual goals, preferences, and values of those living with the disease. library.ehaweb.org/eha/2025/eha20…

#EHA2025, it's a wrap! Thank you to all our delegates, faculty and partners for joining us in Milan for 3.5 days of learning and connection. We look forward to seeing you again next year in Stockholm from 11-14 June for #EHA2026. Save the date!

Double Defense: Ibrutinib–Venetoclax Outshines Solo Therapy and FCR in CLL Summary: In the phase 3 FLAIR trial for chronic lymphocytic leukemia (CLL), the combination of ibrutinib and venetoclax significantly outperformed both ibrutinib alone and the traditional FCR regimen. At

Updates from #EHA2025 nejm.org/doi/full/10.10…

Breaking News from #EHA2025 Flair Trial results: High rates of undetectable MRD and progression free survival in combination treatment Ibrutinib plus venetoclax. Unfortunately, it was not approved in Ireland despite its approval in over 80 countries. Jan Rynne

Presented at #EHA2025: Among patients with CLL undetectable MRD and progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone or chemoimmunotherapy, with benefits sustained at 5 years. Full FLAIR phase 3 trial nej.md/3SMNdC4

Dr Brian Healey Bird Gerry Hanna NHS England CancerTrialsIreland 🌈 Seamus O’Reilly MD PhD Jennifer Carroll MacNeill TD Jarushka Naidoo bbc.co.uk/news/articles/… The Sherry family have suffered the consequences of this inequity in access to cancer trials. My heart breaks for them. #CancerHasNoBorders Mike Nesbitt #cancertrials #CancerAwareness 💔🙏

The recordings from our recent joint conference with CLL Ireland are now available to watch on our YouTube channel youtube.com/playlist?list=…

Few understand the challenges faced more than those experiencing them. Great patient-led #research survey on impact of #ProstateCancer treatment on sexual & mental health still open & looking for contributions from patient & partners. Please share 🙏 cancertrials.ie/proact-survey/

Breaking: Big news for smoldering myeloma. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a new indication for DARZALEX®(daratumumab) subcutaneous (SC) formulation as monotherapy for the treatment

Cancer in Ireland: We manufacture and export €250 billion in pharmaceutical products here in Ireland but when it's come to access cutting edge cancer treatments we have the lowest access in the EU Germany approved 54 new cancer meds to Irelands 14. Colm Burke TD Paul McAuliffe TD

Help us mark the beginning of Blood Cancer Awareness Month at our Hillsborough Forest Park Walk on Sunday 31st August. This gentle walk takes in the beautiful surroundings of Hillsborough Forest at dusk and is suitable for all. llni.co.uk/event/hillsbor…

The Trinity St James’s Cancer Institute has become the first & only cancer centre in Ireland to be accredited as a Comprehensive Cancer Centre. This achievement marks a significant undertaking by Trinity College Dublin & St James's Hospital who jointly established the Trinity St James's Cancer Institute.